Semax and Selank: Neuropeptide Research into BDNF Signaling, GABAergic Pathways, and Cognitive Biology

Overview: Two Neuropeptides, Two Mechanisms

Semax and Selank are both synthetic heptapeptides developed from Russian neuropeptide research programs. Despite their similar structural format — both are seven amino acids with a Pro-Gly-Pro C-terminal extension that confers resistance to enzymatic degradation — they act through distinct primary mechanisms and are studied in different areas of neuroscience research.

Semax is derived from the ACTH(4-7) sequence (Met-Glu-His-Phe) and is studied primarily for its effects on neurotrophic factor expression, particularly BDNF and NGF. Selank is an analogue of the naturally occurring immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg) and is studied for its effects on GABAergic signaling, enkephalin metabolism, and immune-nervous system crosstalk. Together they offer researchers two distinct entry points into neuropeptide pharmacology.

Semax: ACTH-Derived Neuropeptide Research

Semax (MEHFPGP) is a synthetic analogue of the ACTH(4-10) melanocortin sequence, though its sequence does not activate melanocortin receptors at research concentrations. Its characterized in vitro activity centers on modulation of neurotrophic factor expression in neuronal cell models.

BDNF and NGF Upregulation
The most studied molecular effect of Semax in neuronal cell lines is upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) gene expression. In cortical neuron cultures, hippocampal cell lines, and neuroblastoma cell models (SH-SY5Y, PC12), Semax treatment has been associated with increased BDNF mRNA expression as measured by qPCR and increased BDNF protein secretion as measured by ELISA.

BDNF acts through TrkB receptors and is a key mediator of synaptic plasticity, neuron survival, and dendritic growth. In cell-based models, BDNF elevation downstream of Semax treatment has been studied for its effects on TrkB/Akt signaling, CREB phosphorylation, and expression of plasticity-related immediate early genes (Arc, Zif268).

Dopaminergic System Research
Semax has also been studied in models investigating the dopaminergic system. In dopaminergic cell line models, researchers have examined whether Semax-driven BDNF upregulation translates into changes in dopamine receptor expression, dopamine transporter (DAT) activity, and dopaminergic neuron survival under stress conditions. This line of research situates Semax within the broader context of neurotrophic support for catecholaminergic neurons.

Neuroprotection Models
In vitro neuroprotection models expose neuronal cells to ischemic conditions (oxygen-glucose deprivation, OGD), glutamate excitotoxicity, or hydrogen peroxide-induced oxidative stress, then assess whether Semax pre-treatment or co-treatment reduces cell death (measured by LDH release, Annexin V staining, or caspase-3 activation). The proposed mechanism of neuroprotection links Semax-driven BDNF/NGF upregulation to activation of TrkB/TrkA survival signaling pathways that counteract apoptotic cascades.

Selank: Tuftsin Analogue and GABAergic Research

Selank (TKPRPGP) is a synthetic analogue of tuftsin — a naturally occurring tetrapeptide fragment of IgG that is produced in the spleen and has characterized immunomodulatory activity. The Pro-Gly-Pro extension in Selank confers greater metabolic stability than native tuftsin, enabling its use in cell culture systems where peptidase activity would otherwise rapidly degrade the parent molecule.

GABAergic Modulation
The most studied aspect of Selank's in vitro pharmacology is its relationship with GABA-A receptor signaling. Research in neuronal cell lines and primary cortical neuron cultures has examined whether Selank influences GABA-A receptor subunit expression, GABA-evoked chloride current amplitudes, and benzodiazepine-site binding characteristics.

The proposed mechanism is indirect — Selank does not appear to directly bind GABA-A receptors at the GABA binding site but may modulate the expression of receptor subunit compositions that affect overall GABAergic tone. Researchers use patch-clamp electrophysiology in primary neuron cultures alongside Western blotting for specific GABA-A subunits (α1, α2, β2, γ2) to characterize these effects.

Enkephalin Metabolism Research
Selank's effects on enkephalin metabolism represent another active research area. Enkephalins are endogenous opioid pentapeptides that modulate pain, stress response, and immune function. Research has examined whether Selank treatment affects the activity of enkephalin-degrading enzymes — specifically enkephalinases (neprilysin, aminopeptidase N) — in neural cell models, potentially modulating endogenous opioid tone via enzyme inhibition rather than direct receptor binding.

Immune-Nervous System Crosstalk
Given Selank's tuftsin lineage, researchers have also studied its effects at the interface of the immune and nervous systems. In microglia models and mixed neuronal-glial cultures, Selank's influence on cytokine production (IL-6, TNF-α, IL-10), microglial activation states (M1 vs. M2 polarization markers), and neuroinflammatory signaling pathways has been characterized using ELISA, flow cytometry, and transcriptomic approaches.

Comparative Research: Semax vs. Selank

While Semax and Selank share structural similarities (both are synthetic heptapeptides with Pro-Gly-Pro extensions), their research applications are complementary rather than overlapping:

Researchers studying neuropeptide pharmacology often use both compounds in parallel experiments to compare and contrast their effects on a shared readout (e.g., neuronal survival, synaptic marker expression) — providing a comparative dataset that helps map the pharmacological landscape of synthetic neuropeptide research tools.